Researchers in the Netherlands found that although adolescents with cystic fibrosis had a higher breathing response to exercise, they were able to breathe adequately enough to be able to perform a moderate exercise task. Cystic fibrosis is one of the most commonly occurring chronic diseases of the lungs…
News
Corbus Pharmaceuticals has been invited to present during this Thursday’s VirtualInvestorConferences.com on its lead pipeline product Resunab™, indicated for the treatment of serious inflammatory and fibrotic diseases, namely cystic fibrosis and diffuse scleroderma. Representing the company during the upcoming online, live event is CEO Yuval Cohen,…
The Arkansas Chapter of the Cystic Fibrosis Foundation held another successful edition of its Breath of Life Gala last Tuesday, November 25th at the Marriott Hotel in Little Rock. The fundraising event, which has become a tradition in Arkansas, gathered 360 guests and featured a candid speech from Katherine Lambert-Pennington,…
Nottingham University Hospital NHS Trust in the U.K. has announced a new state of the art facility utilizing technology from enterprise partners, including Cisco. The new £6.6 million East Midlands Cystic Fibrosis Adult CF Centre campus at Nottingham University Hospital’s (NUH) NHS Trust City Hospital is designed to…
Bayer HealthCare, a global leader in respiratory medicine, recently announced it has received qualified infectious disease product (QIDP) designation from the US Food and Drug Administration for two pipeline inhalation antibiotic drugs: Amikacin inhale and Ciprofloxacin dry powder. The approval of novel inhaled antibiotics are of particular interest to the…
In the United Kingdom, The Cystic Fibrosis Trust along with the children’s charity Action Medical Research, are funding a laboratory test of an inhaled treatment targeting lung dehydration in Cystic Fibrosis. Cystic fibrosis (CF) is a condition that usually affects children and young people and includes symptoms such…
Last month, the Cystic Fibrosis Foundation celebrated the 20th year of its annual golf tournament and successful fundraiser, the Ultimate Golf Experience. Over 100 longtime members and supporters of the CFF gathered at the Pinehurst Resort in Durham in North Carolina, where the golfing-fundraising tradition for CF first…
New research on the mechanism of infection of the bacteria Pseudomonas aeruginosa entitled “Surface attachment induces Pseudomonas aeruginosa virulence” by Dr. Albert Siryaporn at Princeton University was recently published in PNAS. The findings are particularly important to the Cystic Fibrosis community, as Pseudomonas aeruginosa is a serious…
Anthera Pharmaceuticals, Inc., a biopharmaceutical company that specializes in research and development of novel treatments for serious and fatal diseases such as lupus, lupus with nephrotic affectation, and exocrine pancreatic insufficiency (EPI) secondary to cystic fibrosis (CF), has just announced that it has partnered with Patheon®, a contract development and commercial…
Cempra, Inc received clearance to initiate Phase 1b and Phase 2 / 3 studies that will test their solithromycin antibiotic in newborn to 17 year-old patients. The experimental antibiotic could eventually offer new therapeutic options to cystic fibrosis patients in fighting bacterial lung infections. Intravenous, oral suspension formulas, and…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.